Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...
Pfizer ( PFE +0.26%) and Eli Lilly ( LLY +1.80%) are two prominent names in healthcare that have focused on innovation and ...
22hon MSN
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...
Novo Nordisk’s next-gen medication is called CagriSema. It’s a once-weekly shot that combines a long-acting amylin analogue ...
Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...
Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or ...
According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival's ...
The report estimates that out-of-pocket costs for the 10 drugs will fall nearly 50% in 2026 versus 2025 in all 56 stand-alone prescription drug plans in California, Florida, Texas, New York, and ...
Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...
Three stocks that did well during the last big bear market in 2022 are AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and ...
More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.
20hon MSN
Study finds 40% of GLP-1 prescriptions go unfilled: Is cost curbing use of weight loss drugs?
Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback